inflamed.communityinflamed.community

What makes axial spondyloarthritis difficult to manage? A qualitative study of patient and rheumatologist perspectives

Fakih Olivier · 2026 · The Journal of Rheumatology

Reading the original? How to read a paper.

What this paper found

Interviews with French patients who had been through three or more biologics, and their rheumatologists, found they describe difficult-to-manage disease differently: patients talk about pain, fatigue and what they can no longer do, while doctors talk about not being able to tell inflammation from other causes. Much of what makes AS hard to manage is the conversation itself, not only the biology.

Why this is on the map

The patient-voice complement to the two prevalence papers on difficult-to-manage axSpA.

On the map under this thread

Read the paper at the source →

DOI: 10.3899/jrheum.2026-0336 · opens in a new tab. The full paper is on the publisher’s site, not here.

Related papers on the board

Papers sharing one or more threads with this one.

Rydning PNF · 2026
Study

Long-term functional and radiological outcomes among survivors of ankylosing spondylitis-associated cervical spine fractures: a cross-sectional follow-up study.

North American Spine Society journal

Among 97 survivors of neck fractures linked to ankylosing spondylitis, followed for a median of four years, most lived independently with mild neck pain and low disability, 96 percent of fractures had healed solidly, and half of those with spinal cord injury recovered fully. These fractures are dangerous at the time, but for those who come through them the long-term picture is better than most people would expect.

Treatment Response & Outcomes
Sun Tiantian · 2026
Study

Plasma Proteomics Identifies Molecular Signatures and Biomarkers Associated with High Structural Damage in Ankylosing Spondylitis

Arthritis & Rheumatology

Measuring hundreds of blood proteins in people with ankylosing spondylitis, researchers found a five-protein signature, driven by platelet and tissue-remodelling proteins rather than classic inflammation markers, that identified those with heavy structural damage with high accuracy in a separate validation group. Bone damage in AS seems to run partly on a different track from inflammation, and a blood test for it looks feasible.

Treatment Response & Outcomes
Felten Renaud · 2026
Study

Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys

Joint Bone Spine

Surveys of French women with spondyloarthritis and their rheumatologists found that pregnancy is not discouraged and usually goes well, but women rated their worry about flares highly, had gaps in knowledge about biologics in pregnancy and delivery, and only a quarter of rheumatologists knew the pregnancy guidelines. The information gap is on both sides of the consultation.

Treatment Response & Outcomes
Bae Y · 2026
Study

Risk of peripheral artery disease following ankylosing spondylitis, 2012–2023: a nationwide cohort study in South Korea

Scandinavian Journal of Rheumatology

Following 2,846 people with ankylosing spondylitis and ten times as many matched controls in South Korea for four years, AS was linked to a 40 percent higher rate of peripheral artery disease, with the largest excess in women under 60. Circulation in the legs is another thing to keep an eye on, especially for younger women with AS.

Treatment Response & Outcomes